MGRX vs HIMS vs MNMD vs AMWL vs TDOC

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 51. 6x trailing P/E (52. 8x forward), making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +129. 4%, compared to -99. 5% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MGRX's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mangoceuticals, Inc.

(MGRX) is the lower-risk stock at 0. 90β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 166% more volatile than MGRX relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -1294. 4% for MGRX. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TDOC: 13.

8% to $7. 58.

In this comparison, MGRX (100.

0% yield) pays a dividend. HIMS, MNMD, AMWL, TDOC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mangoceuticals, Inc.

(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 5%, TDOC: -38. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MGRX is a small-cap income-oriented stock; HIMS is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock; AMWL is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. MGRX pays a dividend while HIMS, MNMD, AMWL, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.